← All indications
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
Subtype terms (2)
More specific conditions that are subtypes of Carcinoma, Squamous Cell in the MeSH hierarchy.
- Esophageal Squamous Cell Carcinoma
128 drugs (47 approved, 81 experimental)
- Squamous Cell Carcinoma of Head and Neck
775 drugs (219 approved, 556 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (8)
Phase 3 trials (37)
- capecitabine
- pembrolizumab
- velimogene aliplasmid
- l-epigallocatechin
- durvalumab
- proxinium
- retinoic acid
- bevacizumab
- erlotinib
- ifosfamide
- palifermin
- atezolizumab
- dusquetide
- mitomycin
- human papillomavirus 9-valent vaccine, recombinant
- irinotecan
- indocyanine green
- amifostine
- fludeoxyglucose f-18
- vinorelbine
- nicotinamide
- tretinoin
- naltrexone
- cytokine induced killer cells
- mrna-4157
- calcipotriene
- topotecan
- talimogene laherparepvec
- afatinib
- pemetrexed
- +7 more
Phase 2 trials (205)
- dasatinib
- imgatuzumab
- adebrelimab
- Filgrastim
- gimeracil
- nintedanib
- tbio-6517
- l19il2
- T4-bacteriophage endonuclease V
- transcon tlr7/8 agonist
- buparlisib
- cdx-1140
- selinexor
- enfortumab vedotin
- cabozantinib
- cobimetinib
- diphenhydramine
- mdna11
- proflavine
- soybean
- bortezomib
- isa 101
- msk-2206
- cue-101
- camrelizumab
- nm21-1480
- lapatinib
- indomethacin
- lapachone
- multivitamins
- +175 more
Phase 1 trials (93)
- kb707
- berzosertib
- curcumin
- 13c-pyruvate
- sl-279252
- xl092
- tbio-4101
- sasanlimab
- vrp-encapsulated sarna encoding il-12
- 18f fpm
- ct-0508
- bivatuzumab mertansine
- onalespib
- 7-hydroxystaurosporine
- entolimod
- t3011
- ank-101
- prilocaine
- gz17-6.02
- rm-1995
- efineptakin alpha
- fluorothymidine
- Avasopasem
- ad-magea3
- personalized neoantigen vaccine
- dkn-01
- pertuzumab
- hf10
- azacitidine
- mocetinostat
- +63 more
Organizations
Organization Involved with Phase 4 Indications (17)
- Baxalta
- University of Zurich
- Health Bureau of Mian Yang
- Medical University Innsbruck
- Dalian Medical University
- Jiao Tong University
- Nanjing NingQi Medicine Science and Technology Co., Ltd.
- National Health Service, United Kingdom
- Merck
- University of Electronic Science and Technology of China
- Shanghai Xuhui District Central Hospital
- Mianyang Central Hospital
- Department of Veteran Affairs
- Chinese Academy of Medical Sciences
- Luye Pharma
- Simcere Pharmaceutical Co., Ltd
- University of Oxford
Organization Involved with Phase 3 Indications (143)
- Central South University
- Vical
- Innogene Kalbiotech Pte. Ltd
- Pfizer
- Karolinska Institute
- Danish Center for Interventional Research in Radiation Oncology
- University of Antwerp
- Japan Clinical Oncology Group
- The Second People's Hospital of Sichuan
- European Organisation for Research and Treatment of Cancer
- Ferrer Internacional S.A.
- Ono Pharmaceuticals
- Hebei University
- Royal Marsden Hospital NHS Trust
- Xiamen University
- Government of Taiwan
- Sanmenxia Central Hospital
- China Medical University
- Chimei Medical Center
- Anyang Regional Hospital
- Swami Rama Cancer Hospital and Research Institute
- Grupo de Investigación Clínica en Oncología Radioterapia
- University of Indonesia
- Incyte
- Changhua Christian Hospital
- University of Birmingham
- Peking University
- Tianjin Medical University
- Maastricht University
- National Cancer Institute (NCI)
- +113 more
Organization Involved with Phase 2 Indications (324)
- Ningxia Medical University
- Celldex Therapeutics
- Dynavax Technologies Corporation
- Spanish Oncology Genito-Urinary Group
- University of California, San Francisco
- Glycotope GmbH
- NanoCarrier Co., Ltd.
- Curie Manavata Cancer Center, Nashik, India
- Cascadian Therapeutics Inc.
- Australasian Gastro-Intestinal Trials Group
- Hospital Virgen Blanca (León)
- Hengrui Therapeutics, Inc.
- Verastem, Inc.
- Exelixis
- Gruppo Oncologico del Nord-Ovest
- Takeda
- PCI Biotech AS
- Alphamab Co., Ltd.
- Eli Lilly
- Medical College of Wisconsin
- Sunshine Lake Pharma Co., Ltd.
- Imclone
- Cornell University
- Medisch Spectrum Twente
- Brown University
- University of Salamanca
- Regional Cancer Centre, Trivandram
- Prince of Songkla University
- Aventis
- AperiSys, Inc
- +294 more
Organization Involved with Phase 1 Indications (76)
- Mirati Therapeutics Inc.
- Fiverings Co., Ltd.
- Jacobio Pharmaceuticals Co., Ltd.
- Immune Cell Therapy Inc.
- Siemens
- Rowan University
- AbbVie
- Baromedical Research Foundation
- British Columbia Cancer Agency
- Ozmosis Research Inc.
- Miltenyi Biotec, Inc.
- Cairo University
- National Cancer Center, Japan
- Summa Health System
- University of Iowa
- Jennerex Inc.
- Providence Health & Services
- Vyriad, Inc.
- BioClever 2005 S.L.
- Morphogenesis, Inc.
- Vasgene Therapeutics, Inc
- Xencor
- Taizhou Mabtech Pharmaceutical Co., Ltd.
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Aceragen, Inc/
- University of Ottawa
- Schering-Plough
- American Cancer Society, Inc.
- Galera Therapeutics
- Cleveland BioLabs
- +46 more
Organization Involved with Other Experimental Indications (25)
- Zuyderland Medisch Centrum
- Hong Kong Nasopharyngeal Cancer Study Group Limited
- University of Bern
- Rhode Island Hospital
- Jiangsu Cancer Institute & Hospital
- Isala Clinics, Zwolle, The Netherlands
- University of Western Ontario
- The Hong Kong Nasopharyngeal Cancer Study Group
- The University of Hong Kong
- Changhai Hospital
- Deventer Ziekenhuis
- Government of Korea
- Ningbo No. 2 Hospital
- Government of Hong Kong
- NuBiyota
- Naestved Hospital
- University of Southern Denmark
- University of Groningen
- Verbeeten Insituut Tilburg
- Shiyan Taihe Hospital
- Rijnstate Hospital
- DUSA Pharmaceuticals
- University of Toyama
- Stemirna Therapeutics
- Government of Mexico